Loading
The freshest signals in cancer: new papers, trial results, approvals and law, updated with every build.
Ranked newest first, with approvals, withdrawals and phase 3 results counting as two weeks fresher than their date, other results, law and papers in the leading journals one week fresher, and preprints one week older; every kind keeps its most recent items so no filter is empty while its source has data. Within a day the weightier items come first. Pick types to combine them; For you narrows to the cancer chosen in For me (a choice that stays in this browser); the first filter reads the full 500-item feed.
200 items on this page.
817 changelog entries, 1 upcoming date, 8 corrections.
openFDA has a label for "Aspirin".
EMA register: Casgevy (exagamglogene autotemcel) Authorised, 2024-02-09.
EMA register: Cystagon (mercaptamine bitartrate) Authorised, 1997-06-23.
EMA register: Entyvio (vedolizumab) Authorised, 2014-05-22.
EMA register: Libmeldy (autologous CD34+ cells encoding ARSA gene) Authorised, 2020-12-17.
EMA register: Lumeblue (previously Methylthioninium chloride Cosmo) (methylthioninium chloride) Authorised, 2020-08-19.
EMA register: Lynkuet (elinzanetant) Authorised, 2025-11-17.
EMA register: NeoRecormon (epoetin beta) Authorised, 1997-07-16.
EMA register: Nezglyal (leriglitazone) Authorised, 2026-09-21.
EMA register: Procysbi (mercaptamine) Authorised, 2013-09-05.
EMA register: SomaKit TOC (edotreotide) Authorised, 2016-12-08.
EMA register: Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) Authorised, 2016-05-26.
EMA register: Waskyra (etuvetidigene autotemcel) Authorised, 2026-01-09.
EMA register: Xromi (hydroxycarbamide) Authorised, 2019-07-01.
EMA register: Yartemlea (Narsoplimab) Opinion under re-examination.
EMA register: Zefylti (filgrastim) Application withdrawn.
ClinicalTrials.gov overall status is RECRUITING; recorded positive.
ClinicalTrials.gov overall status is RECRUITING; recorded positive.
ClinicalTrials.gov overall status is RECRUITING; recorded positive.
ClinicalTrials.gov overall status is TERMINATED; recorded positive.
Published in Nat Rev Clin Oncol on 1 October 2026; matched the OnCo record for Enfortumab vedotin.
Published in Nat Rev Clin Oncol on 1 October 2026; matched the OnCo record for Primary CNS lymphoma.
Published in Zhonghua Yi Xue Yi Chuan Xue Za Zhi on 1 October 2026; matched the OnCo record for RPS19.
Published in Lancet Child Adolesc Health on 1 October 2026; matched the OnCo record for Logic-gated therapeutics.
Published in Clin Nephrol on 1 October 2026; matched the OnCo record for ATP7B.
Published in Eur Thyroid J on 1 October 2026; matched the OnCo record for DICER1.
Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for Sintilimab.
Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for INHBB.
Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for Claudin 18.2.
Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for Pleural mesothelioma.
Published in Physiother Res Int on 1 October 2026; matched the OnCo record for Sentinel lymph node biopsy.
Published in Acta Physiol (Oxf) on 1 October 2026; matched the OnCo record for MPEG1.
Published in Int J Clin Pharmacol Ther on 1 October 2026; matched the OnCo record for AFF1.
Published in Liver Int on 1 October 2026; matched the OnCo record for TBK1.
Published in J Appl Clin Med Phys on 1 October 2026; matched the OnCo record for In-room imaging for radiotherapy.
Published in Protein Sci on 1 October 2026; matched the OnCo record for CTAG1B.
Published in Liver Int on 1 October 2026; matched the OnCo record for FOLFIRI.
Published in Pharmacol Res Perspect on 1 October 2026; matched the OnCo record for Cytarabine.
Published in Glia on 1 October 2026; matched the OnCo record for CX3CL1.
Published in Pak J Pharm Sci on 1 October 2026; matched the OnCo record for Nilotinib.
Published in Physiother Res Int on 1 October 2026; matched the OnCo record for Inflammatory myofibroblastic tumour.
Published in Neuropathology on 1 October 2026; matched the OnCo record for Primary CNS lymphoma.
Published in Protein Sci on 1 October 2026; matched the OnCo record for PSPC1.
Published in J Biochem Mol Toxicol on 1 October 2026; matched the OnCo record for CCNE1.
Published in J Appl Clin Med Phys on 1 October 2026; matched the OnCo record for Gamma Knife.
Published in Cancer on 1 October 2026; found by the roadmap watch for ARCHES.
Published in J Appl Clin Med Phys on 1 October 2026; matched the OnCo record for VDR.
Published in Aust N Z J Obstet Gynaecol on 1 October 2026; matched the OnCo record for Progestins.
Published in Urol Oncol on 1 October 2026; matched the OnCo record for Multiparametric prostate MRI.
Published in Clin Transl Sci on 1 October 2026; matched the OnCo record for Fruquintinib.
Published in Int J Med Robot on 1 October 2026; matched the OnCo record for Luminal androgen receptor triple-negative breast cancer.
Published in Pharmacol Res Perspect on 1 October 2026; matched the OnCo record for RB1.
Published in Microbiologyopen on 1 October 2026; matched the OnCo record for MT-CO1.
Published in J Immunother on 1 October 2026; matched the OnCo record for Tocilizumab.
Published in Cancer on 1 October 2026; matched the OnCo record for Advanced-stage classical Hodgkin lymphoma.
Published in Liver Int on 1 October 2026; matched the OnCo record for EP300.
Published in Dis Mon on 1 October 2026; matched the OnCo record for Pancreatic neuroendocrine tumours.
Published in J Cachexia Sarcopenia Muscle on 1 October 2026; matched the OnCo record for CT body composition and sarcopenia measurement.
Published in Biosci Rep on 1 October 2026; matched the OnCo record for SNCAIP.
Published in Basic Clin Pharmacol Toxicol on 1 October 2026; matched the OnCo record for FOXO1.
Published in Clin Plast Surg on 1 October 2026; matched the OnCo record for Propranolol.
Published in Anim Genet on 1 October 2026; matched the OnCo record for SOX9.
Published in Neuropathol Appl Neurobiol on 1 October 2026; matched the OnCo record for SMARCB1.
Published in Neuropathology on 1 October 2026; matched the OnCo record for CIC.
Published in J Immunother on 1 October 2026; matched the OnCo record for Extensive-stage small-cell lung cancer.
810 changelog entries, 1 upcoming date, 12 corrections.
Published in Cancer on 1 October 2026; matched the OnCo record for TET2.
Published in J Cachexia Sarcopenia Muscle on 1 October 2026; matched the OnCo record for REST.
Published in Hematol Oncol Clin North Am on 1 October 2026; matched the OnCo record for Gastrointestinal stromal tumour.
Published in Glia on 1 October 2026; matched the OnCo record for AXL.
Published in Pancreas on 1 October 2026; matched the OnCo record for Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors.
Published in Neuropathology on 1 October 2026; matched the OnCo record for DICER1.
Published in Cancer Cytopathol on 1 October 2026; matched the OnCo record for Mucoepidermoid carcinoma.
Published in Int J Dev Neurosci on 1 October 2026; matched the OnCo record for Gamma-secretase.
Published in J Med Primatol on 1 October 2026; matched the OnCo record for Medullary thyroid cancer.
Published in Pak J Pharm Sci on 1 October 2026; matched the OnCo record for Capecitabine.
Published in Biomed Chromatogr on 1 October 2026; matched the OnCo record for Ceralasertib.
Published in Physiother Res Int on 1 October 2026; matched the OnCo record for Salivary duct carcinoma.
Published in J Pept Sci on 1 October 2026; matched the OnCo record for Mia.
Published in J Immunother on 1 October 2026; matched the OnCo record for Talimogene laherparepvec.
Published in J Hepatol on 1 October 2026; matched the OnCo record for Floxuridine.
Published in J Genet Couns on 1 October 2026; matched the OnCo record for FH.
Published in Clin Teach on 1 October 2026; matched the OnCo record for Small intestine cancer.
797 changelog entries, 1 upcoming date, 14 corrections.
802 changelog entries, 1 regulatory event, 1 upcoming date, 8 corrections.
795 changelog entries, 1 regulatory event, 1 upcoming date, 8 corrections.
Published on 28 September 2026 after first appearing as a preprint; matched CCDC6.
Published on 28 September 2026 after first appearing as a preprint; matched MET.
Posted on bioRxiv on 28 September 2026; not peer reviewed; matched Immune checkpoint inhibitors, PD-1 and State.
Posted on Research Square on 28 September 2026; not peer reviewed; matched MRI, AI in radiology and State.
Posted on bioRxiv on 28 September 2026; not peer reviewed; matched State.
Posted on medRxiv on 28 September 2026; not peer reviewed; matched ELL.
Posted on Research Square on 28 September 2026; not peer reviewed; matched HPV & HBV vaccination, Chemoprevention & risk-reducing surgery and State.
Posted on bioRxiv on 28 September 2026; not peer reviewed; matched State and CCDC6.
Posted on Research Square on 28 September 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and Doxorubicin.
Posted on bioRxiv on 28 September 2026; not peer reviewed; matched CAR-T cell therapy.
Posted on medRxiv on 28 September 2026; not peer reviewed; matched MRI and SET.
Posted on Research Square on 28 September 2026; not peer reviewed; matched Fluorouracil.
Posted on bioRxiv on 28 September 2026; not peer reviewed; matched TSC1, VHL and NFE2L2.
Posted on bioRxiv on 28 September 2026; not peer reviewed; matched Proteomics & phosphoproteomics, Ruxolitinib and MEK1/2.
Posted on Research Square on 28 September 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and AKT.
Posted on bioRxiv on 28 September 2026; not peer reviewed; matched Single-cell & spatial profiling, Liquid biopsy and Spatial transcriptomics.
Posted on bioRxiv on 28 September 2026; not peer reviewed; matched CD44 and Galectin-9.
Published on 27 September 2026 after first appearing as a preprint; matched Ultrasound.
Published on 27 September 2026 after first appearing as a preprint; matched Active surveillance and ELL.
760 changelog entries, 1 regulatory event, 1 upcoming date, 8 corrections.
Published on 26 September 2026 after first appearing as a preprint; matched Pathology & radiology foundation models.
Published on 26 September 2026 after first appearing as a preprint; matched Doxorubicin and VWF.
Published on 26 September 2026 after first appearing as a preprint; matched CD30, CT and ALK.
Published on 26 September 2026 after first appearing as a preprint; matched Temozolomide, Single-cell & spatial profiling and Patient-derived organoids.
Published on 26 September 2026 after first appearing as a preprint; matched Erythropoietin receptor and STAT5.
Published in J Clin Oncol on 25 September 2026; found by the roadmap watch for STELLAR.
Published on 25 September 2026 after first appearing as a preprint; matched Sunitinib.
Published on 25 September 2026 after first appearing as a preprint; matched CFLAR.
Published on 25 September 2026 after first appearing as a preprint; matched H3C14.
Published on 25 September 2026 after first appearing as a preprint; matched State.
Published on 25 September 2026 after first appearing as a preprint; matched KLK2 and KLK3.
Published on 25 September 2026 after first appearing as a preprint; matched Germline (hereditary) testing.
Published on 25 September 2026 after first appearing as a preprint; matched Cytotoxic chemotherapy.
Published on 25 September 2026 after first appearing as a preprint; matched KRAS, TP53 and ELL.
Published on 25 September 2026 after first appearing as a preprint; matched Atlas, FLG and SET.
Published on 25 September 2026 after first appearing as a preprint; matched Bispecific antibodies, CD3 and HLA-A.
Published on 25 September 2026 after first appearing as a preprint; matched State, Mismatch repair proteins and MLH1.
On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
Published on 24 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, GATA2 and STAG2.
Published on 24 September 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing and ATM.
Published on 24 September 2026 after first appearing as a preprint; matched State, ASCL1 and OLIG2.
Published on 24 September 2026 after first appearing as a preprint; matched PROTACs & molecular glues.
Published on 24 September 2026 after first appearing as a preprint; matched Exercise & lifestyle oncology.
Published on 24 September 2026 after first appearing as a preprint; matched Nintedanib, Whole-exome & whole-genome sequencing and Single-cell & spatial profiling.
Published on 24 September 2026 after first appearing as a preprint; matched BTK, Pirtobrutinib and State.
Published on 24 September 2026 after first appearing as a preprint; matched Fedratinib, JAK2 and MPL.
On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.
Published in Endocr Relat Cancer on 23 September 2026; matched the OnCo record for CYP11B1.
Published on 23 September 2026 after first appearing as a preprint; matched Elongation factor 2 and State.
Published in Adv Sci (Weinh) on 23 September 2026; matched the OnCo record for HMGA2.
Published in Gut Microbes on 23 September 2026; matched the OnCo record for SIRT1.
Published in Mol Oncol on 23 September 2026; matched the OnCo record for ARID1A.
Published on 23 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.
Published in Am J Physiol Cell Physiol on 23 September 2026; matched the OnCo record for HEY1.
Published in Acta Oncol on 23 September 2026; found by the roadmap watch for SOLAR-1.
Published on 23 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.
Published in J Cell Sci on 23 September 2026; matched the OnCo record for FGD1.
Published on 23 September 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and Ki-67.
Published in Comput Methods Biomech Biomed Engin on 23 September 2026; matched the OnCo record for SLC6A2.
Published on 23 September 2026 after first appearing as a preprint; matched Optical & fluorescence imaging, Liquid biopsy and MIR21.
Published in J Int Med Res on 23 September 2026; matched the OnCo record for RNASET2.
Published in Funct Integr Genomics on 23 September 2026; matched the OnCo record for HRAS.
Published on 23 September 2026 after first appearing as a preprint; matched MGMT.
Published on 23 September 2026 after first appearing as a preprint; matched Topotecan, EGFR and Topoisomerase I.
Published in Nat Med on 22 September 2026; found by the roadmap watch for PATHFINDER 2.
Published in Nat Med on 22 September 2026; found by the roadmap watch for NHS-Galleri.
Published in Cell on 22 September 2026; matched the OnCo record for IRF1.
Published in Cancer Discov on 22 September 2026; matched the OnCo record for BMP2.
Published in Blood on 21 September 2026; matched the OnCo record for LMNA.
On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Published in J Clin Oncol on 18 September 2026; matched the OnCo record for Early-stage classical Hodgkin lymphoma.
Published in Cancer Discov on 18 September 2026; matched the OnCo record for Amivantamab.
Published in Cancer Cell on 18 September 2026; matched the OnCo record for Zoledronic acid.
Published in Science on 17 September 2026; matched the OnCo record for RaDaR.
Published in Cancer Discov on 17 September 2026; matched the OnCo record for YL201.
Published in Nat Med on 17 September 2026; matched the OnCo record for Diffuse midline glioma, H3 K27-altered.
Published in Ann Oncol on 17 September 2026; matched the OnCo record for Goserelin / leuprolide.
On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Accelerated approval (Etcamah) The confirmatory requirement was still open 0.0 years later, when the FDA's table was read.
On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
Withdrawn: the indication came off the label 2.3 years after its accelerated approval.
NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.: dolutegravir.
On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Subcutaneous formulation (PALOMA-3).
On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
Withdrawn: the indication came off the label 6.4 years after its accelerated approval.
Withdrawn: the indication came off the label 6.0 years after its accelerated approval.
Withdrawn: the indication came off the label 5.9 years after its accelerated approval.
Programme deprioritised after regulatory feedback on Duravelo-2 design.
For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State: Arm A: Lazertinib With Amivantamab SC-CF 206 micrograms per milliliters (mcg/ml) versus Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion 144 micrograms per milliliters (mcg/ml).
Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator: BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone 25.99 months, hazard ratio 0.515.
Overall Survival (OS): Nofazinlimab + Lenvatinib 21.6 months versus Placebo + Lenvatinib 18.5 months.
Major Pathological Response (MPR) - IASLC Method: Osimertinib + Chemo 25.6 % versus Osimertinib 24.8 % versus Placebo + Chemo 1.7 %.
Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale: Nivo + Rela FDC SC 4.141 ug/ml versus Nivo + Rela FDC IV 3.901 ug/ml.
Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale: Nivolumab SC 77.373 μg/ml versus Nivolumab IV 36.875 μg/ml versus Nivo SC Process C 75.504 μg/ml versus Nivo SC Process D 75.596 μg/ml.
Progression Free Survival (PFS): Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 8.4 months versus Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 4.4 months, hazard ratio 0.43.
Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis): Asciminib 16 participants versus Nilotinib 34 participants, hazard ratio 0.45.
Median disease-free survival 9.30 against 5.55 months (hazard ratio 0.79, p=0.107): primary endpoint not met.
Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12): Treatment 23.08 % versus Control 13.33 %.
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
Overall survival 17.7 vs 18.0 months (HR 0.92, p 0.32) overall and 20.4 vs 20.4 months (HR 1.05) in PIK3CA/AKT1/PTEN-altered tumours; PFS 5.6 vs 5.1 months (HR 0.72).
Co-primary endpoints including OS met (July 2026); numbers pending.
Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.
Stopped early; primary endpoint not met.
Marketing authorisation withdrawn in the European Union in 2026: Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons).
Marketing authorisation withdrawn in the European Union in 2025: Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025.
Marketing authorisation withdrawn in the European Union in 2025: MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing).
A 2025 EU regulation that gives patients electronic access to their health records across the Union and creates national bodies that can grant researchers, regulators and companies permission to use anonymised or pseudonymised health data, phased in over the rest of the decade.
Everything above is read at build time from snapshots and records already in the repository; nothing is fetched when the page is viewed. Where each kind comes from and how often its source refreshes, from the workflow schedules in .github/workflows:
FDA Oncology Center of Excellence approval notifications (public/fda/recent.json), dated approvals recorded on product pages, and European Commission authorisations from the regional approvals table with an EPAR or regulator link.
Refresh: FDA feed Wednesdays 06:07 UTC (refresh-fda.yml); EU rows checked against the EMA register Wednesdays 06:37 UTC (refresh-regional.yml); product pages by hand.
Dated withdrawals recorded on product pages and withdrawn EU authorisations in the regional approvals table, each with a source link.
Refresh: Same schedule as approvals.
Trials in the corpus with a reported year and structured outcomes, linked to the primary paper, sponsor release or registry entry the outcome cites.
Refresh: Curated by hand; ClinicalTrials.gov status refreshed Mondays 06:17 UTC (refresh-trials.yml).
The newest Europe PMC matches for every product, target, cancer and technology (public/papers), journal versions of tracked preprints, and papers the roadmap watch found for landmark trials. One entry per DOI, however many records it matched.
Refresh: Literature snapshot Tuesdays 05:41 UTC (refresh-papers.yml); roadmap watch Thursdays 05:29 UTC (roadmap-watch.yml).
bioRxiv, medRxiv, Research Square and other preprints of the last 90 days that match a target, product or technology query (public/preprints). Not peer reviewed.
Refresh: Wednesdays 06:17 UTC (refresh-preprints.yml).
Statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made, each linked to its primary text.
Refresh: Curated by hand; new instruments are added when they are enacted.
Changes the nightly bot proposes for the corpus from the FDA feed, the EMA register and registry status changes (public/proposals/latest.json). Proposals, not facts: each waits for a human to apply it.
Refresh: Daily 03:23 UTC (propose.yml).
OnCo's own weekly issue: what changed, regulatory events, upcoming readouts and what the journals published.
Refresh: Mondays 07:31 UTC (newsletter.yml); the archive is rebuilt with every deploy.
Dates are shown at the precision the source gives: a year-only law or authorisation is grouped under its year, never given a day. Papers are matched to records by their literature queries, so a code or a common word can pull in an unrelated paper; the record chips tell you what matched. Not medical advice.